Free Weekly Diagnostics Newsletter. Get the latest news on Market Launches, M&A and Partnership Deals, Clinical Milestones, and more sent straight to your Inbox. Join fellow diagnostics developers and manufacturers who subscribe to FierceDiagnostics for FREE!

A team at the University of California, San Diego (UCSD), has found biomarkers for ovarian tumors by mining two National Institutes of Health-sponsored databases. The bioinformatics-enabled research program has raised expectations that earlier diagnoses of ovarian cancer can be made, an advance that could improve outcomes in a tough therapeutic indication.

AstraZeneca has detailed the data from two of three studies of its late-stage combination program for lesinurad, a new drug for gout obtained in their $1.26 billion buyout of Ardea, which showed that the treatment hit the desired biomarker for blood levels of uric acid as promised--but added today that it failed to actually reduce the rate of painful flare-ups of the disease for patients in the study.

The busy partners at Atlas Venture have gathered together a $17 million Series A for their latest biotech creation: Quartet Medicine, which pairs together two scientific founders who have been exploring the frontiers of pain management. This is Atlas' fourth maiden round for one of their biotech launches in a little more than a week, with Cambridge, MA-based Quartet joining Unum, Raze and Bicycle in a rare streak of startups. And there are likely some more to come.

Virginia Tech researchers believe they've found a possible biomarker to help detect a rare genetic disease known as severe combined immunodeficiency, or SCID, which leaves patients needing to avoid all human contact and breathe filtered air in order to survive.

Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.

Medical device evaluation can only be as effective as the tools used to conduct the evaluation. The FDA has begun seeking applications for the Medical Device Development Tools Pilot Program to validate and review such tools in preparation for a final guidance on the topic.

Join 20,000+ Insiders

SIGN UP FOR OUR NEWSLETTER

FierceDiagnostics is the first place diagnostics developers and manufacturers turn to for industry news on market launches,M&A and partnership deals,clinical milestones, and more. Sign up for your free, weekly email newsletter today!

THE LIBRARY: WEBINAR

This webinar will discus how the emergence of the ability to share documents and data across thousands of miles instantly has pulled biopharma companies in two opposing directions. Companies want, even need, the interconnectivity that is facilitated by the Internet, but feel equally strongly about controlling who can view and interact with their data. Register today!

FierceDiagnostics is the first place diagnostics developers and manufacturers turn to for industry news on market launches,M&A and partnership deals,clinical milestones, and more. Click here to get your free weekly email briefing today!